Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raoul Tibes

Showing results (21-30 of 75) with videos related to

Pageof 8
Sort By:
Cancer Epidemiology|September 15, 2015
Epidemiology of adult acute myeloid leukemia: Impact of exposures on clinical phenotypes and outcomes after therapyLaura Finn, Lisa Sproat, Michael G Heckman, et al.
International Journal of Clinical Oncology|October 12, 2012
Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphomaDaruka Mahadevan, Donald W Northfelt, Pavani Chalasani, et al.
British Journal of Cancer|June 6, 2018
Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 studyRaoul Tibes, Mitesh J Borad, Corina E Dutcus, et al.
Blood|October 9, 2008
Functional proteomic profiling of AML predicts response and survivalSteven M Kornblau, Raoul Tibes, Yi Hua Qiu, et al.
Molecular Cancer|August 20, 2010
RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcomaShilpi Arora, Irma M Gonzales, R Tanner Hagelstrom, et al.
Cancer Medicine|January 24, 2013
18-FDG PET/CT assessment of basal cell carcinoma with vismodegibCurtis A Thacker, Glen J Weiss, Raoul Tibes, et al.
Computational and Structural Biotechnology Journal|May 22, 2020
Corrigendum to "Triazolo[4,5-<i>d</i>]pyrimidines as validated general control nonderepressible 2 (GCN2) protein kinase inhibitors reduce growth of leukemia cells" [Comput. Struct. Biotechnol. J. 16 (2018) 350-360]Lea Lough, Dan Sherman, Manuel Becerra-Flores, et al.
American Journal of Hematology|January 10, 2023
A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expressionAref Al-Kali, Raoul Tibes, Pamela Atherton, et al.
Cancer|May 12, 2006
Activity of alemtuzumab in patients with CD52-positive acute leukemiaRaoul Tibes, Michael J Keating, Alessandra Ferrajoli, et al.
Cancer|April 12, 2023
Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasmsRaoul Tibes, Heidi E Kosiorek, Amylou C Dueck, et al.
Pageof 8

Showing results (21-30 of 75) with videos related to

Sort By:
Pageof 8
Cancer Epidemiology|September 15, 2015
Epidemiology of adult acute myeloid leukemia: Impact of exposures on clinical phenotypes and outcomes after therapyLaura Finn, Lisa Sproat, Michael G Heckman, et al.
International Journal of Clinical Oncology|October 12, 2012
Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphomaDaruka Mahadevan, Donald W Northfelt, Pavani Chalasani, et al.
British Journal of Cancer|June 6, 2018
Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 studyRaoul Tibes, Mitesh J Borad, Corina E Dutcus, et al.
Blood|October 9, 2008
Functional proteomic profiling of AML predicts response and survivalSteven M Kornblau, Raoul Tibes, Yi Hua Qiu, et al.
Molecular Cancer|August 20, 2010
RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcomaShilpi Arora, Irma M Gonzales, R Tanner Hagelstrom, et al.
Cancer Medicine|January 24, 2013
18-FDG PET/CT assessment of basal cell carcinoma with vismodegibCurtis A Thacker, Glen J Weiss, Raoul Tibes, et al.
Computational and Structural Biotechnology Journal|May 22, 2020
Corrigendum to "Triazolo[4,5-<i>d</i>]pyrimidines as validated general control nonderepressible 2 (GCN2) protein kinase inhibitors reduce growth of leukemia cells" [Comput. Struct. Biotechnol. J. 16 (2018) 350-360]Lea Lough, Dan Sherman, Manuel Becerra-Flores, et al.
American Journal of Hematology|January 10, 2023
A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expressionAref Al-Kali, Raoul Tibes, Pamela Atherton, et al.
Cancer|May 12, 2006
Activity of alemtuzumab in patients with CD52-positive acute leukemiaRaoul Tibes, Michael J Keating, Alessandra Ferrajoli, et al.
Cancer|April 12, 2023
Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasmsRaoul Tibes, Heidi E Kosiorek, Amylou C Dueck, et al.
Pageof 8